[go: up one dir, main page]

BRPI0417206A - forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol - Google Patents

forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol

Info

Publication number
BRPI0417206A
BRPI0417206A BRPI0417206-0A BRPI0417206A BRPI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A
Authority
BR
Brazil
Prior art keywords
crystalline form
oxoethanol
pyrimidin
piperidin
fluorophenyl
Prior art date
Application number
BRPI0417206-0A
Other languages
English (en)
Inventor
Richard R Schartman
Doug H Hoffmann
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0417206A publication Critical patent/BRPI0417206A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMA CRISTALINA DE 2-{4-3-(4-CLORO-2-FLUOROFENIL)-4-PIRIMIDIN-4-IL-1H-PIRAZO L-5-IL!PIPERIDIN-1-IL)-2-OXOETANOL". Forma cristalina do inibidor de p38 cinase 2-{4-¢3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1H-pirazol-5-íi!piperidin-1- il}-2-oxoetanol é fornecido. A forma cristalina é uma forma cristalina hidratada. Também fornecidas são combinações e composições farmacêuticas compreendendo a forma cristalina, processo para preparo da forma cristalina e para preparo de composições compreendendo a forma cristalina, e métodos para a profilaxia e/ou tratamento da condição mediada por p38 cinase compreendendo administração a um indivíduo de uma quantidade terapeuticamente eficaz da forma cristalina de 1.
BRPI0417206-0A 2003-12-19 2004-12-15 forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol BRPI0417206A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53076303P 2003-12-19 2003-12-19
PCT/IB2004/004187 WO2005061486A1 (en) 2003-12-19 2004-12-15 Crystalline form of 2-{4-‘3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl!piperidin-1-yl}-2-oxoethanol

Publications (1)

Publication Number Publication Date
BRPI0417206A true BRPI0417206A (pt) 2007-02-06

Family

ID=34710178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417206-0A BRPI0417206A (pt) 2003-12-19 2004-12-15 forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol

Country Status (7)

Country Link
US (1) US20070142412A1 (pt)
EP (1) EP1697346A1 (pt)
JP (1) JP2007514734A (pt)
BR (1) BRPI0417206A (pt)
CA (1) CA2550283A1 (pt)
MX (1) MXPA06006813A (pt)
WO (1) WO2005061486A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511743A1 (en) * 2002-06-05 2005-03-09 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.

Also Published As

Publication number Publication date
MXPA06006813A (es) 2006-12-19
EP1697346A1 (en) 2006-09-06
JP2007514734A (ja) 2007-06-07
CA2550283A1 (en) 2005-07-07
WO2005061486A1 (en) 2005-07-07
US20070142412A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
MX2009000333A (es) Pirrilopirimidinas para composiciones farmaceuticas.
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
BR0116605A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
SE0202429D0 (sv) Novel Compounds
NO20073465L (no) Benzotiazol-derivater
SE0202462D0 (sv) Novel use
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
GB0112348D0 (en) Compounds
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NO20091185L (no) Piperidinderivater
SE0301232D0 (sv) Novel use
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
SE0302756D0 (sv) Novel Compounds
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
SE9803773D0 (sv) Compounds
BRPI0417206A (pt) forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]